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Abstract  
 
Background: Real-life data on vedolizumab effectiveness in inflammatory bowel disease 
(IBD) are still emerging. Data on the comparative safety of the gut selective profile are of 
particular interest. 
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Aims: To assess clinical outcome and safety in IBD patients treated with vedolizumab.  
Methods: We retrospectively collected data of patients treated with vedolizumab at eight 
UK hospitals (August 2014-January 2018). Clinical response and remission at 14 and 52 
weeks evaluated through Physician Global Assessment (PGA) and adverse events were 
recorded. Possible predictors of clinical response were examined. 
Results: Two hundred and three IBD patients (mean treatment 16±8 months) were 
included. Of these, 135 patients (mean age 40.6±16.0 years; F:M 1.9:1) had CD and 68 
(mean age 44.5±18.1 years; F:M 1:1.2) had UC. According to PGA, 106/135 (78.5%) CD 
and 62/68 (91.2%) UC patients (p=0.02) had a clinical response/remission at 14 weeks, 
whereas 76/119 (63.9%) CD and 52/63 (82.5%) UC patients (p<0.01) showed a sustained 
response or remission at 52 weeks, with a high adherence rate (97%). No predictors of 
clinical response were found. The cumulative incidence of infectious diseases was 11.9 
per 100 person-years.  
Conclusion: Vedolizumab is an effective therapy for inducing and maintaining remission 
of IBD, with better results for UC, and with a good safety profile. 
 
Abbreviations: CD, Crohn’s disease; CI, confidence interval; CRP, C reactive protein; 
EBV, Epstein-Barr virus; FC, faecal calprotectin; HBI, Harvey-Bradshaw Index; IBD, 
inflammatory bowel disease; IL, interleukin; PGA, Physician Global Assessment; PML, 
progressive multifocal leukoencephalopathy; TNF, tumour necrosis factor; UC, ulcerative 
colitis; VDZ, vedolizumab. 
 
Keywords: biological therapy; clinical predictors; Crohn’s disease; elderly; 
immunomodulator; ulcerative colitis. 
 
Introduction  
Inflammatory bowel disease (IBD) represents a group of chronic, immune-mediated 
conditions with multifactorial aetiology that encompasses two major phenotypes, namely 
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Crohn’s disease (CD) and ulcerative colitis (UC).1,2 The global burden of IBD is high, with 
approximately 3.5 million of people affected in Europe and the United States, and rapidly 
increasing in newly industrialised countries.3 IBD increases the overall risk of death,4 and 
adversely affects quality of life. All these considerations highlight the need for optimal 
management, comprising highly effective existing and novel medications with an 
acceptable risk-benefit profile. 
Medical treatment of IBD has evolved over the last two decades, particularly since the 
introduction of biological therapies. Anti-tumour necrosis factor (TNF) α agents (infliximab, 
adalimumab, certolizumab pegol, and golimumab) were the first monoclonal antibodies 
used for the treatment of IBD.5 A significant proportion of patients treated with anti-TNF 
agents experience primary non-response or secondary loss or response.6-9 Further, there 
is a risk of relapse after discontinuation10 and a small increase in the risk of infections and 
some types of cancer.11 The evolving understanding of the immunopathogenesis of IBD 
has led to the development of other biological therapies. Natalizumab was the first anti-
integrin monoclonal antibody to be used in the treatment of CD with moderate efficacy;12,13 
its use in clinical practice was limited by the death of a patient in the ENACT study due to 
progressive multifocal leukoencephalopathy (PML) from reactivation of the John 
Cunnigham (JC) virus as a consequence of non-selective 41 inhibition.14 Vedolizumab 
(VDZ) is a humanised, gut-selective monoclonal IgG1 antibody that targets the 
heterodimer α4β7 integrin, inhibiting migration and leukocytes adhesion.15 The landmark 
trials GEMINI 1,16 2,17 and 318 showed that VDZ is effective in both CD and UC, with 
similar remission rates compared to anti-TNFs.19 The long-term GEMINI safety studies and 
post hoc analyses confirmed an acceptable safety profile and efficacy,20,21 regardless 
previous exposure to anti-TNFs22,23 and age groups.24 However, clinical trials do not 
necessarily reflect everyday practice, as real-life use may differ considerably in terms of 
patient selection. A number of real-life studies regarding VDZ have been published, 
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reporting novel - but sometimes conflicting - results, including possible clinical predictors of 
response and new safety signals.25-35 
The aim of this study was to describe our clinical experience with VDZ, defining its 
effectiveness and safety in inducing and maintaining remission in IBD patients treated in 
eight different hospitals across northern England. 
 
Methods        
 
Patients 
Eight IBD centres (belonging to both university and general hospitals) from the UK 
participated in this study (Leeds Teaching Hospitals; Manchester Royal Infirmary; Salford 
Royal Hospitals; Bolton NHS Trust; Bradford Teaching Hospital; The Royal Liverpool and 
Broadgreen University Hospitals; Wrightington, Wigan and Leigh NHS Trust; The Pennine 
Acute Hospitals). We retrospectively collected data of all IBD patients (age ≥ 18) initiated 
on VDZ (August 2014 – June 2017; last follow up January 2018) through the local 
electronic medical records. All patients had an established diagnosis of CD or UC 
according to internationally agreed diagnostic criteria.36,37 Data were extracted and 
anonymised from patient records onto a pre-defined spreadsheet that was centrally 
collated at the coordinating site (St. James’s University Hospital, Leeds). All queries 
regarding uncertain data were resolved via email through consensus with the study 
coordinator (MVL). VDZ was given as an intravenous infusion (300 mg) over thirty minutes 
at week 0, 2, 6, and every 8 weeks thereafter. A number of centres gave an additional 
week 10 dose for the indication of CD only (12 patients), if clinically indicated, and in a few 
patients, the infusion interval was shortened to 4 weekly. Demographic (age, gender) and 
disease data (phenotype according to the Montreal classification,38 disease duration, 
previous medications, previous surgery) were evaluated. Other variables of interest 
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considered were concomitant steroid and immunosuppressive therapies, bridging steroid 
therapy, smoking status, previous exposure to any biologic therapies, and adherence to 
planned infusions. All the required items for observational cohort studies were included 
according to STROBE recommendations. 
 
Outcomes 
Our primary outcome measure was clinical response or remission at 14 (just before 
commencing maintenance therapy) and 52 weeks (±2 weeks) assessed using the 
Physician Global Assessment (PGA) score. PGA outcomes were based on the clinical 
impression of the local investigator, defining remission as the complete relief or marked 
improvement of symptoms compared to baseline, and response as a partial, though 
significant, improvement. In order to corroborate PGA results, we also evaluated the 
Harvey-Bradshaw Index (HBI)39 for CD and the partial Mayo score for UC,40 when 
available (either prospectively, recorded in clinic letters, or retrospectively, derived from 
clinic letters). Compared to the baseline, remission was defined with a HBI ≤ 4 or a partial 
Mayo score ≤ 1 without any bleeding, while a reduction of 3 or more points of both scoring 
systems defined clinical response. Furthermore, we collected data on C reactive protein 
(CRP) and faecal calprotectin (FC) at baseline and at 14 weeks (±1 week), when available. 
As secondary outcome, we assessed potential predictors of clinical response, including, 
among others, bridging steroid therapy, concomitant use of immunosuppressant 
(azathioprine, 6-mercaptopurine, or methotrexate), previous anti-TNF exposure, smoking 
status, disease duration, baseline FC and CRP, disease phenotype and location for CD, 
disease extension for UC, and previous surgery. As third outcome, we looked at reasons 
for discontinuation, all the adverse events, infectious diseases, and other safety signals or 
disorders that were related to VDZ therapy that occurred from overall exposure to VDZ 
until end of follow-up. A sub-analysis of elderly patients (≥ 65 years old) was performed. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., 
California, USA). Non-parametric tests were used to analyse continuous variables, and 
absolute and relative frequencies to describe categorical variables. Categorical data were 
summarised as the percentage of the total group according to disease type (CD, UC). 
Differences in continuous variables between two groups were analysed using the 
nonparametric Mann-Whitney U-test for unpaired samples (as not all variables were 
available in all patients). Chi-squared test was used for comparison of proportions. The 
degree of correlation between HBI or partial Mayo score and PGA (1=remission; 2=partial 
response; 3=non-response or worsening) at 14 and 52 weeks was assessed with 
nonparametric two-tailed Spearman’s rank correlation coefficient. Two-sided Fisher’s exact 
test was used to compare categorical data between the two groups, along with the 95% 
confidence interval (CI) and odds ratio. A p-value of <0.05 was considered as statistically 
significant. Effectiveness outcomes for 14 weeks were reported on an intention-to-treat 
basis, while 52-week effectiveness data used the number of patients entered into 
maintenance therapy as the denominator.  
 
Ethical standards 
The study was performed as a clinical audit using routine collected clinical data and as 
such is exempt from the need for ethics committee approval in the UK and the need to 
take written informed consent.  
 
Results 
 
Cohort 
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After excluding 22 patients with insufficient data, we included 203 patients with IBD (mean 
age 41.9±16.8 years; F:M 1.4:1) treated with VDZ for a mean period of 16±8 months 
(range 1-37 months). Demographic and relevant clinical characteristics are reported in 
Table 1. Notably, 27/203 patients (13.3%; mean age 72.4±4.7 years, 17 females; 14 CD 
and 13 UC) were ≥ 65 years old (elderly subgroup) and 13/27 (48.1%) had at least two 
associated chronic diseases, namely essential hypertension, chronic heart failure, 
diabetes mellitus type 2, and chronic obstructive pulmonary disease. Among all patients 
with CD, 27/135 (20.0%) had at least one previous abdominal IBD-related surgical 
intervention (including partial colectomy, small-bowel resections), 56/135 (41.5%) had 
been exposed to one anti-TNF α, and 73/135 (54.1%) had been exposed to at least two 
different biological therapies (any anti-TNF α agents or/and ustekinumab). Among patients 
with UC, 40/68 (58.8%) have been exposed to one anti-TNF α, and 5/68 (7.3%) have been 
exposed to two different anti-TNF α agents.  
 
Clinical effectiveness 
According to PGA, 106/135 (78.5%) CD and 62/68 (91.2%) UC patients (p=0.02) had a 
clinical response or remission at 14 weeks, whereas 76/119 (63.9%) CD and 52/63 
(82.5%) UC patients (p<0.01) showed a sustained response or remission at 52 weeks. 
Steroid-free remission was particularly high in the studied population (Figure 1). Figure 1 
shows the 14- and 52-week response rates and steroid-free remission according to 
disease type and Table 2 reports the trend of HBI or partial Mayo score, along with the 
inflammatory markers (CRP, FC). Clinical activity indexes (HBI and partial Mayo score) 
had a decreasing trend over time (p<0.01) (Supplementary Table 1). Moreover, a 
significant positive correlation between HBI/partial Mayo score and PGA was found at both 
14 (r=0.588, 95% CI 0.469-0.687, p<0.01) and 52 (r=0.728, 95% CI 0.608-0.816, p<0.01) 
weeks, thus confirming PGA results. Similarly, both FC and CRP showed a decreasing 
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trend at 14 weeks, even if this was statistically significant only for FC. In five patients VDZ 
therapy was intensified (one escalated to six weekly, four escalated to four weekly). 
Furthermore, 13/135 (9.6%) CD patients had an additional dose at week 10. In the elderly 
subgroup, 12/14 (85.7%) CD and 12/13 (92.3%) UC patients had a clinical response to the 
induction therapy (p=ns), whereas 11/14 (78.6%) CD and 10/13 (76.9%) UC patients 
maintained response at 52 weeks (p=ns). The rate of concomitant immunosuppressant in 
the elderly group was 13/27 (48.1%) vs 88/176 (50.0%) of the adult group (p=ns), whereas 
the rate of steroid use at baseline was 16/27 (59.2%) vs 78/176 (44.3%), respectively 
(p=ns). 
 
Continuation of VDZ and safety outcomes 
Table 2 shows the timing of VDZ discontinuation (≤14 weeks, >14 and ≤52 weeks, >52 
weeks) and the related reasons or subsequent management. Overall, 71 patients (34.9%) 
discontinued VDZ after an average time of 7±4 months (7±4 months for CD; 7±5 months 
for UC; p=ns). We reported one case of death, which occurred in a 39-year old male 
patient with a longstanding history of CD, who had had multiple intestinal resections and a 
permanent ileostomy, due to intestinal obstruction. This patient had been on VDZ for 29 
months and had previously experienced primary or secondary non-response to three 
different anti-TNF α agents and ustekinumab. Non-adherence to VDZ was reported in 
6/203 (2.9%) patients. We considered a number of potential predictive factors of clinical 
response at 14 and 52 weeks (Supplementary Tables 2 and 3), and only the use of 
bridging steroid therapy in CD patients showed a negative association at 14 weeks (OR 
0.403; 95% CI 0.1746-0.9332; p=0.0339) with steroid exposed patients less likely to 
experience response to VDZ. However, after adjusting this variable for disease severity at 
baseline (mean HBI 10.2±4.7 vs 8.4±4.1; p=0.03), the association was lost. Moreover, 
gender, disease behaviour, disease location, and previous surgery for CD, and gender and 
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disease extension for UC were not predictive of clinical response (p=ns). Finally, Table 3 
summarises all the adverse events, infectious diseases, and other disorders or safety 
signals attributed to VDZ therapy. Adverse events and infectious diseases were fatal, 
though led to VDZ discontinuation in 16 patients (7.8%, Table 2). At least one infection 
occurred in 8/52 (15.4%) patients on VDZ monotherapy compared to 20/151 (13.2%) 
patients on any concomitant immunosuppressive drug (including steroids; p=0.692). 
However, among the 28 patients who had at least one infection, this occurred in 8 (28.6%) 
who were on VDZ monotherapy and in 20 (71.4%) who were also taking another 
immunosuppressive drug (p<0.01; 10/28 [35.7%] an immunomodulator, 6/28 [21.4%] 
steroid therapy, and 4/28 [14.3%] both immunomodulator and steroid therapy). Admission 
at hospital for infectious diseases occurred in 11/28 (39.3%) patients. The cumulative 
incidence of non-infective adverse events and infectious diseases were 5.1 per 100 
person-year and 11.9 per 100 person-years, respectively. No cases of PML were reported 
in our cohort. No infectious diseases were seen in the elderly subgroup. 
 
Discussion 
 
Our multicentre experience of eight IBD Units across Northern England is the largest study 
from the United Kingdom to date showing that VDZ is an effective and safe therapy in real-
world practice for both the induction and maintenance of remission of CD and UC. Patients 
with UC had a better clinical response at both 14 and 52 weeks compared to CD. VDZ 
demonstrated high effectiveness and safety even in the subgroup of elderly patients with 
multiple co-morbidities. Unlike previous studies,26,27,29,31,33,41 we have not found possible 
predictors of clinical response.  
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Since VDZ was approved for the treatment of IBD in 2014, further evidence has 
demonstrated long-term efficacy and safety. However, many unresolved issues require 
further clarification, in particular regarding the usefulness of concomitant 
immunosuppressive therapy and steroids, and the definition of possible predictors of 
clinical response. Ongoing debate over its placement in the biological treatment algorithm 
requires further effectiveness and safety data. In our cohort, we found a cumulative 
induction and maintenance response/remission rate for both CD and UC, generally higher 
than previous registration trials and in keeping with other long-term analyses.16,17,20,21 
However, in our series UC patients experienced higher maintained response rates than 
those with CD. Compared to a recent pooled analysis of real-world data,42 52-week 
response/remission rate was lower in our series (63.9% vs 86%) for CD. This finding may 
have different explanations. Our CD population had a high rate of patients who failed to 
multiple biological therapies or had bowel resections. On the contrary, our UC population 
had a high rate of anti-TNFs naïve patients with a disease extension limited to the left 
colon. HBI and Mayo score significantly decreased at 14 weeks, with a further decrease at 
52 weeks (p<0.01 vs baseline, Supplementary Table 1). Accordingly, CRP and FC 
decreased at 14 weeks, but this was statistically significant for FC only.  
 
The medical therapy of IBD poses a particular challenge in the elderly population that is 
more likely to suffer from multimorbidity with a higher risk of negative outcomes. We 
therefore sub-analysed the efficacy and safety of VDZ in the subgroup of patients ≥ 65 
years. VDZ proved to be effective, and no infectious diseases were reported. In a previous 
small case series of elderly patients, a few adverse events, including respiratory tract and 
gastrointestinal infections, were reported. 43 VDZ may represent a good choice for these 
patients, but more prospective studies are needed. 
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Additionally, we looked at potential predictors of clinical response (Supplementary Tables 
2 and 3) according to the literature,26,27-29,31,32,41,42 but the analysis failed to demonstrate 
any statistical association. In contrast to post hoc GEMINI trials analyses being anti-TNF α 
naïve was not associated with a better response.,22,23 Data from real-world series show 
conflicting results.26,27,30,31,41 For CD our analysis may lack statistical power but for UC a 
greater proportion of patients were anti-TNFs naïve. Also, CRP and FC at baseline failed 
to discriminate patients who were more likely to achieve remission or response. A few real-
world studies found a negative association between high disease activity and high CRP at 
baseline and clinical remission.26,27,29,33  
 
Whether bridging steroid therapy and/or immunosuppressants increase VDZ response rate 
is still a matter of debate. Similar to the registration trials,16,17the retrospective consortium 
study from the US,31 and the Swedish National Registry30 we found no association of 
concomitant immunosuppressants with response. In contrast, one retrospective analysis in 
CD patients reported that the addition of an immunomodulator after induction improved 
odds of clinical response at 52 weeks, acting as salvage therapy.41 In The risk-benefit 
balance of immunomodulator therapy needs to be considered and as the majority of 
infections occurred in patients on combination therapy clinicians should routinely re-
evaluate the need for immunosuppressive therapy in patients on VDZ.  
    
The role of dose escalation or intensification with VDZ remains unresolved. Five patients 
achieved remission after escalation of therapy (to six weekly in one patient and to four 
weekly in the others) and 13 CD patients had an additional dose at week 10. Data 
regarding dose escalation are still scanty, but this strategy proved efficacious in the long-
term GEMINI studies.20,21  
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Primary or secondary non-response were the leading causes (Table 2) for VDZ 
discontinuation (46/203, 22.6%), while six patients (2.9%) were not adherent to the 
planned VDZ infusions. This is the first report of non-adherence in patients treated with 
VDZ. Non-adherence to medication is an essential, though often underestimated, problem 
in IBD patients, where beliefs and concerns may have a negative impact.44,45  
 
Overall, we encountered low rates of adverse events. Among these, five led to 
discontinuation (four urticarial rash and one supraventricular tachycardia during VDZ 
infusion). The cumulative incidence of non-infective adverse events of 5.1 per 100 person-
year is much lower than that found in long-term GEMINI studies,20,21 (we did not include 
disease progression as an adverse event however). We reported a relatively high 
occurrence of headache and paraesthesia, in keeping with other studies.33,46 The single 
case of miscarriage occurred in a 27-year old female with CD who had received 6 VDZ 
infusions and voluntarily decided to stop the infusions and subsequently flared. Pregnancy 
outcomes in patients treated with VDZ are still largely unknown.42 
 
Unsurprisingly, among the infectious diseases, nasopharyngitis and pneumonia were the 
most represented. We reported a cumulative incidence of infectious diseases of 11.9 per 
100 person-year (13.7% of the whole cohort), that is comparable to the other real-life 
studies (range 1.7%-12.6%).46 We reported two VDZ discontinuation in relation to 
significant viral infections in our cohort: a case of viral meningitis  and a case of Epstein-
Barr virus (EBV) infection with acute hepatitis. Both of these patients were on concomitant 
immunosuppressive therapy. A life-threatening case of fungal sepsis occurred in a 23-year 
old male who was on concomitant methotrexate and systemic steroid therapy. The only 
case of tuberculosis reactivation affecting the central nervous system occurred in a 57-
year old female suffering from type 2 diabetes.  
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Our study has some limitations. First, the retrospective nature may lead to possible biases, 
such as the over- or underestimation of PGA. We tried to overcome this obstacle using a 
standardised spreadsheet with uniform data, also comprising HBI and partial Mayo score 
that showed a significant positive correlation with PGA. A similar method has already been 
used for the retrospective assessment of clinical efficacy of a biological therapy.48 Second, 
it is known that FC may have a between-assay variability49 and the hospitals that took part 
in the study may have used different FC assays, thus producing variations in results. Minor 
adverse events and infections might have not been reported by patients or have not been 
recorded in local electronic records, therefore our results may underestimate the incidence 
as described in clinical trials. Nevertheless, we have reported novel and interesting 
insights that should be further investigated. 
 
In summary, we have here described our 2-year long, real-life, multicentre experience with 
VDZ since it was approved for the treatment of IBD. Based on clinical and laboratory 
grounds, VDZ proved to be an effective and safe drug, even in this cohort of predominantly 
anti-TNF α exposed patients and in a subgroup of elderly patients.  
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Figure legend 
 
Figure 1. 14- and 52-week remission and response rates and steroid-free remission 
according to the Physician Global Assessment. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
 23 Lenti MV et al. 
 23 
 
Table 1. Demographic and other relevant characteristics of patients treated with 
vedolizumab.  
 Crohn’s disease Ulcerative colitis 
   
N. patients 135 68 
 
Age (years), mean ± SD 40.6 ± 16.0 44.5 ± 18.1 
 
F:M ratio 1.9:1 1:1.2 
 
Duration of disease (months), mean ± 
SD 107 ± 96  84 ± 62 
 
Disease phenotype, n (%) Ileal, 15 (11.1%) Proctitis, 3 (4.4%) 
 
Colonic, 34 (25.2%) 
Left sided colitis, 44 
(64.7%) 
 Ileocolonic, 67 (47.4%) 
Upper, 11 (8.1%) 
Perianal, 16 (11.9%) 
Pancolitis, 18 (26.5%) 
N/A= 3 
 Inflammatory, 35 
(25.9%) 
 
 Stricturing, 31 (22.9%)  
 Penetrating, 27 
(20.0%) 
 
 N/A= 17  
Smoking status   
 
      Current smoker, n (%) 20 (14.8%) 1 (1.5%) 
 
      Former smoker, n (%) 13 (9.6%) 23 (33.8%) 
 
Any prior anti-TNF α exposure, n (%) 129 (95.5%) 45 (66.2%) 
 
*Concomitant immunosuppressive 
therapy, n (%) 70 (51.8%) 31 (45.6%) 
 
Bridging steroid therapy 
 
51 (37.7%) 46 (67.6%) 
*This includes: azathioprine, methotrexate, or 6-mercaptopurine. Abbreviations: N/A, not 
available; SD, standard deviation; TNF, tumour necrosis factor. 
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Table 2. Patients who discontinued 
vedolizumab and related reasons for 
discontinuation or loss of response.  
 Crohn’s 
disease 
Ulcerative 
colitis 
   
Discontinuation ≤14 weeks, n (%) 
 
Adverse effect 
Abscess development 
Need of surgery 
Infection  
Non-adherence 
9/135 (6.6%) 
 
2 
2 
3 
1 
1 
3/68 (4.4%) 
 
/ 
/ 
3 
/ 
/ 
 
Discontinuation >14 and ≤52 weeks, n (%) 39/107 (36.4%) 10/61 (16.4%) 
   
Adverse effect 5 1 
Loss of response (switch to other agent) 16 4 
Need of surgery 11 3 
Infection 4 1 
Non-adherence 3 1 
 
Discontinuation >52 weeks, n (%) 8/80 (10.0%) 2/53 (3.8%) 
   
             Adverse effect 1 / 
Loss of response (switch to other agent) 1 1 
Need of surgery 3 1 
Infection 1 / 
Death (intestinal obstruction) 1 / 
Non-adherence 1 / 
 
Total discontinuations 
 
56/135 (41.5%) 15/68 (22.1%) 
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Table 3. Adverse events, 
infectious diseases, and other 
disorders reported during 
vedolizumab therapy, regardless 
its discontinuation. More than one 
event may have occurred within 
the same patient. 
 
 
Crohn’s 
disease 
Ulcerative 
colitis 
Total 
    
Adverse events, n 13 1  14 
    
Urticarial rash 3 1  
Itching (without rash) 2 /  
Paresthesia  2 /  
Hypotension 1 /  
Supraventricular tachycardia 1 /  
Headache 3 /  
Miscarriage 1 /  
    
Infectious diseases, n  23 8  31 
    
Nasopharyngitis 6 3  
Pneumonia 5 3  
Perianal sepsis 3 /  
Skin bacterial infection 2 /  
Scarlett fever / 1  
Urinary tract infection 1 1  
Viral meningitis 1 /  
Herpes zoster (shingles) 1 /  
Epstein-Barr infection 1 /  
Fungal sepsis 1 /  
Cryptosporidium gastroenteritis 1 /  
Central nervous system tuberculosis 1 /  
    
Other disorders, n  4  3  7  
    
Lichen planus 1 /  
Iron deficiency anaemia 1 /  
Abnormal liver function tests 1 1  
Rectal muscle spasm / 1  
Worsening of psoriasis 1 /  
Atrial mixoma / 1  
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